Sarah Boyce, Avidity Biosciences CEO
Avidity CEO says it's ‘full steam ahead’ in DMD as stock rallies on Phase 1/2 win
The Duchenne muscular dystrophy community received some rare good news on Friday when Avidity Biosciences reported surprisingly positive clinical results in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.